Time to metastasis after prostatectomy should not be used as a prognostic factor for metachronous mHSPC

Combining chemotherapy with cemiplimab for advanced penile cancer may serve as a viable first-line treatment option

KIM-1 is a good prognostic and predictive biomarker in advanced renal cell carcinoma

UGN-102 shows better results after 12 months of treatment for low-grade intermediate-risk NMIBC

Mobile prostate cancer screening clinic can help address barriers to serving high-risk communities

177Lu-PSMA-617 with concomitant ARPIs shows is more efficacious than SoC in mCRPC

CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC

HSD3B1 inheritance reduces OS in high-risk nmPC patients on ADT enzalutamide, abiraterone acetate plus prednisolone

Enfortumab vedotin in combination with pembrolizumab shows improved survival rates in la/mUC

Prostate cancer

Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC compared to standard of care

Pembrolizumab shows improvement in overall survival for clear cell renal cell carcinoma